¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"supporting reactions"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • delayed hemolytic transfusion reactions
    Áö¿¬¼º¿ëÇ÷¼º¼öÇ÷¹ÝÀÀ
  • donor reactions
    ÇåÇ÷ÀÚ ¹ÝÀÀ
  • drug reactions, adverse
    ¾à¹°¹ÝÀÀ(¡­Úãëë), ºÎÀÛ¿ë(ÜùíÂéÄ)
  • free radical formation,redox reactions
    ÀÚÀ¯ ·¡µðÄ® Çü¼º, »êȭȯ¿ø¹ÝÀÀ(ß«ûùü½êªÚãëë)
  • hemolytic transfusion reactions
    ¿ëÇ÷¼º¼öÇ÷¹ÝÀÀ
  • hypersensitivity reactions
    °ú¹Î¼º ¹ÝÀÀ(ΦÚÂàõ Úãëë)
  • hypersensitivity reactions,delayed-type
    Áö¿¬Çü(òÀæÅû¡)
  • hypersensitivity reactions,type i(anaphylactic)
    IÇü
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • hypersensitivity reactions,type iv(cell-mediated)
    IVÇü
  • mixed-field reactions
    È¥Çսþ߹ÝÀÀ
  • nonimmunologic febrile transfusion reactions
    ºñ¸é¿ª¼º ¹ß¿­¼öÇ÷¹ÝÀÀ
  • nonimmunologic hemolytic transfusion reactions
    ºñ¸é¿ª¼º¿ëÇ÷¼öÇ÷¹ÝÀÀ
  • transfusion reactions
    ¼öÇ÷¹ÝÀÀ, ¼öÇ÷ºÎÀÛ¿ë
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÅëÇÕ°Ë»ö ¿Ï·á